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Abstract
Background: The ESCRT (endosomal sorting complex required for transport) machinery
functions to sort cellular receptors into the lumen of the multivesicular body (MVB) prior to
lysosomal degradation. ESCRT components can also be recruited by enveloped viruses to sites of
viral assembly where they have been proposed to mediate viral egress. For example, HIV-1 budding
is dependent on Gag-mediated recruitment of the cellular ESCRTs-I, -III, AIP1/Alix and Vps4
proteins. Viral recruitment of ESCRT proteins could therefore impact on host cell processes such
as receptor downregulation.
Results: Here we show that downregulation of the HIV-1 co-receptor, CXCR4, by its ligand SDF-
1, is ESCRT-I dependent. Expression of HIV-1 Gag attenuated downregulation of CXCR4, resulting
in accumulation of undegraded receptors within intracellular compartments. The effect of Gag was
dependent on an ESCRT-I interacting motif within the C-terminal p6 region of Gag. In contrast,
PMA-induced downregulation of the HIV-1 receptor CD4 was independent of ESCRT-I and Vps4;
HIV-1 Gag had no effect on this process.
Conclusion: These results establish that the HIV-1 receptor, CD4, and co-receptor, CXCR4 are
differentially regulated by ESCRT proteins. HIV-1 Gag selectively modulates protein sorting at the
MVB, interfering with ESCRT-I dependent but not ESCRT-I independent processes.
Background
Many transmembrane receptors that are destined for lyso-
somal degradation are directed through the multivesicular
body (MVB) sorting pathway [1,2]. Internalized receptors
are sorted into endosomal membrane invaginations,
which then pinch off to form intralumenal vesicles within
the MVB. This process is initiated by the ubiquitin-bind-
ing protein, Hrs, which recruits the endosomal sorting
complex required for transport (ESCRT)-I to endosomal
membranes by directly interacting with the ESCRT-I com-
ponent, TSG101 (Tumor Susceptibility Gene 101) [3].
Following ESCRT-I recruitment, ESCRTs-II and III are
sequentially localized to the endosomal membrane [1].
These complexes bind ubiquitylated receptors and are
required for receptor sorting into the lumen of the MVB.
The AAA type ATPase Vps4 then facilitates the disassembly
of the ESCRT complexes prior to membrane fission,
thereby ensuring that these complexes are available for
further rounds of protein sorting [4].
Published: 11 February 2008
Virology Journal 2008, 5:23 doi:10.1186/1743-422X-5-23
Received: 25 January 2008
Accepted: 11 February 2008
This article is available from: http://www.virologyj.com/content/5/1/23
© 2008 Valiathan and Resh; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 14
(page number not for citation purposes)
Virology Journal 2008, 5:23 http://www.virologyj.com/content/5/1/23In many respects, vesicle formation in the MVB is topolog-
ically identical to viral budding at the plasma membrane:
both processes involve budding away from the cytosol.
Most enveloped viruses have evolved strategies to gain
access to cellular ESCRTs in order to mediate virion egress
from the infected cell [5]. For example, HIV-1 recruits
ESCRT complexes to sites of viral assembly through direct
interactions between the Gag polyprotein and two cellular
ESCRT proteins: TSG101 and AIP1/Alix [6-9]. Depletion
of TSG101 or introduction of dominant negative mutants
of AIP1/Alix arrests HIV-1 budding at a late stage and
blocks viral particle release [7,10]. Likewise, depletion of
TSG101 and other ESCRT components inhibits lysosomal
downregulation of ligand-activated growth factor recep-
tors, such as the EGF Receptor (EGFR) [11-13]. Given the
fact that HIV-1 budding and EGFR downregulation both
require ESCRT function, it is logical to question whether
there is competition for cellular ESCRT components when
both processes occur in the same cell at the same time.
We have previously shown that expression of HIV-1 Gag
decreases the rate of EGF induced EGFR degradation [14].
This effect is dependent on the presence of an intact
TSG101-binding sequence within the Gag polyprotein. As
a result, activated EGFR accumulates in late endosomal
compartments and Gag expressing cells exhibit higher lev-
els of activated MAP Kinase. These findings indicate that
HIV-1 Gag impinges upon the normal function of cellular
ESCRT complexes during EGFR downregulation. In order
to determine whether downregulation of other receptors
is sensitive to HIV-1 Gag expression, we have now investi-
gated the kinetics of lysosomal downregulation of CD4
and CXCR4, in the presence and absence of Gag. CD4 and
CXCR4 function as the receptor and co-receptor respec-
tively for the entry of HIV-1 X4 variants into target cells
[15]. Regulation of the cell surface levels of these two pro-
teins is critically important for HIV-1 pathogenesis.
CXCR4 is a seven transmembrane G-Protein Coupled
Receptor (GPCR) expressed on the cell surface of various
leukocytes such as neutrophils, monocytes and lym-
phocytes [16,17]. The ligand for CXCR4 is the chemokine
stromal cell-derived factor (SDF-1), which regulates the
movement of leukocytes during their development,
homeostasis and inflammatory response [18]. Upon SDF-
1 binding, CXCR4 is rapidly phosphorylated by GPCR
kinase (GRK) and internalized via clathrin-coated pits
[19]. SDF-1-bound CXCR4 is also monoubiquitylated by
the Nedd4 like E3 Ub ligase AIP4 [20]; this promotes sort-
ing of CXCR4 into the internal vesicles of the MVB prior
to lysosomal degradation. While Hrs and Vps4 have been
implicated in the lysosomal degradation of monoubiquit-
ylated CXCR4 [20], no study has determined whether the
ESCRT complexes play a role in this process. Hrs and Vps4
have been shown to function in ESCRT-dependent [3] as
well as ESCRT-independent [21] pathways of receptor
sorting. Identifying which of the two Hrs-dependent path-
ways is functional in the lysosomal downregulation of
CXCR4 is important since this may also have implications
for the trafficking of this receptor in HIV-1 infected cells.
CD4 is a transmembrane glycoprotein that is expressed on
the surface of a subset of T cells as well as monocytes and
macrophages. It normally functions as a signal transducer
during T cell activation. Antigens, mitogens and PKC
modulators such as PMA induce internalization of CD4,
thereby regulating its cell surface expression [22,23]. PMA
induces phosphorylation of CD4, resulting in its rapid
internalization from the cell surface and degradation in
lysosomes [24,25]. Similarly, the HIV-1 Nef protein
induces endocytosis and lysosomal degradation of CD4
[26]. Both PMA and Nef-induced CD4 internalization are
dependent on the clathrin adaptor protein AP-2 [27]. The
sorting of CD4 from early endosomes into late endo-
somes/MVBs during Nef-induced downregulation has
been shown to be dependent on the interaction of Nef
with the β subunit of the coatomer protein-(COP)-1 com-
plex and ARF1 [28,29]. How this sorting step occurs dur-
ing PMA-induced CD4 downregulation and whether
ESCRT complexes are involved is not known.
Given the fundamental importance of both CXCR4 and
CD4 for both normal cell physiology and HIV-1 biology,
we have examined the role of ESCRT I in downregulation
of these two cellular proteins. SDF-1-induced downregu-
lation of CXCR4 and PMA-induced downregulation of
CD4 were monitored in cells depleted of endogenous
TSG101 using siRNA directed against TSG101. We also
monitored CXCR4 and CD4 downregulation in cells
expressing HIV-1 Gag. Our findings indicate that SDF-1-
induced CXCR4 downregulation is defective when
ESCRT-I function is impaired, while PMA-induced CD4
downregulation is not. Consequently, the expression of
HIV-1 Gag attenuated CXCR4 downregulation, while hav-
ing little to no effect on CD4 downregulation. These
results have important implications for the endocytic traf-
ficking of CD4 and CXCR4 in normal as well as HIV-1
infected cells.
Results
SDF-1 induced CXCR4 downregulation is ESCRT-I 
dependent
Previous studies have established that SDF-1 induces
internalization, endosomal trafficking and lysosomal deg-
radation of CXCR4 and HA-tagged CXCR4 in a variety of
cell types [19,20,30]. To study the role of TSG101 in
CXCR4 downregulation, we used transfected COS-1 cells
co-expressing GFP and HA-tagged CXCR4. HA-CXCR4 has
previously been shown to be a valid marker for CXCR4
trafficking and degradation in COS-1 cells [19,20]. ThePage 2 of 14
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labeled using an anti-HA antibody. Cells were then incu-
bated with or without SDF-1 for 3 hours. In the absence of
SDF-1, a considerable amount of internalization of HA-
CXCR4 was observed (Fig 1A). This observation confirms
previous reports and likely reflects a combination of con-
stitutive endocytosis [31] and antibody-induced, ligand-
independent endocytosis of CXCR4 [17]. HA-CXCR4 that
was internalized in the absence of SDF-1 appeared in
punctate, endosomal structures and remained unde-
graded. In contrast, cells that were incubated in the pres-
ence of SDF-1 clearly exhibited a loss in receptor signal,
confirming that SDF-1 induces degradation of HA-
CXCR4.
In order to determine whether SDF-1 induced HA-CXCR4
downregulation is dependent on the ESCRT-I complex,
cells were depleted of the critical ESCRT-I component,
TSG101. Addition of siRNA directed against TSG101
resulted in 80% knockdown of endogenous TSG101 lev-
els (Fig. 1B). SDF-1 induced HA-CXCR4 degradation was
significantly attenuated in TSG101-deficient cells (Fig.
1A), as indicated by the retention of receptors in punctate
structures even after 3 hours of incubation with SDF-1. An
alternative method to interfere with TSG101 function was
also implemented. Overexpression of full length TSG101
has been shown to inhibit ESCRT-I function and block
EGF-induced EGFR downregulation [14,32]. COS-1 cells
overexpressing TSG101 also exhibited attenuated HA-
CXCR4 degradation (Fig. 1A). These data indicate that
HA-CXCR4, like EGFR, is dependent on TSG101 function
for SDF-1 mediated degradation.
Expression of HIV-1 Gag inhibits HA-CXCR4 degradation 
in a late-domain dependent manner
Recruitment of ESCRT-I complexes to sites of viral assem-
bly by HIV-1 Gag mediates the separation of viral and host
membranes during the virus release process. We have pre-
viously shown that Gag expression results in the func-
tional depletion of ESCRT-I complexes. EGF induced
EGFR downregulation, an ESCRT-I dependent process,
was attenuated in HIV-1 Gag expressing cells [14]. Since
SDF-1 induced degradation of HA-CXCR4 also appears to
be ESCRT-I dependent, we hypothesized that HA-CXCR4
degradation would also be attenuated in HIV-1 Gag
expressing cells.
To test this hypothesis, COS-1 cells were co-transfected
with plasmids encoding HA-CXCR4 and Gag-GFP (GFP-
tagged HIV-1 Gag). Cells expressing wild type HIV-1 Gag-
GFP exhibited attenuated HA-CXCR4 degradation (Fig
2A). This effect of Gag was dependent on its TSG101-
interacting PTAP sequence, located within the C-terminal
p6 region of the Gag polyprotein. Cells expressing a Gag
PTAP mutant efficiently degraded HA-CXCR4 (Fig. 2A).
HA-CXCR4 degradation efficiencies were quantitated in
cells expressing various GFP-tagged constructs. HA-
CXCR4 degradation was decreased 3–6 fold in cells
expressing TSG101-GFP or Gag-GFP, compared to cells
expressing GFP (Fig 2B). A similar effect was noted in cells
depleted of TSG101. In contrast, CXCR4 degradation in
cells expressing the late domain mutant, LTAL Gag-GFP
was nearly equivalent to that of control cells (Fig 2B).
These results suggest that expression of wild type HIV-1
Gag interferes with the function of endogenous TSG101
and/or ESCRT-I machinery, resulting in increased accu-
mulation of internalized, undegraded HA-CXCR4, follow-
ing SDF-1 treatment.
We next examined whether accumulation of intracellular
HA-CXCR4 caused alterations in SDF-1 mediated signal-
ing. GPCRs are known to be rapidly desensitized after lig-
and binding and internalization. One would therefore
predict that accumulation of intracellular, inactivated
receptors would not alter signaling. To test this hypothe-
sis, the time course of pERK formation, a downstream rea-
dout of SDF-1 mediated CXCR4 signaling, was
monitored. As depicted in Figure 2C, cells expressing Gag-
GFP exhibited identical kinetics and levels of pERK pro-
duction when compared to cells expressing GFP. Thus,
accumulation of intracellular HA-CXCR4 did not result in
altered SDF-1 induced CXCR4 signaling in Gag expressing
cells.
HIV-1 Gag attenuates SDF-1 induced downregulation of 
endogenous CXCR4 in Jurkat T cells
In transfected COS-1 cells, both HA-CXCR4 and HIV-1
Gag were exogenously expressed at high levels. We have
previously shown that the levels of Gag expressed under a
CMV promoter (as in the experiments above) are compa-
rable to HIV-1 LTR-driven Gag expression levels in COS-1
cells and might therefore be representative of the levels of
Gag in an HIV-1 infected cell [14]. In order to examine the
effects of Gag expression on endogenous CXCR4, we
monitored the kinetics of SDF-1 induced downregulation
of CXCR4 in Jurkat T cells. Jurkat cells express endogenous
CXCR4, and are authentic targets of HIV-1 infection in
vivo. Therefore, studying the effects of HIV-1 Gag expres-
sion on CXCR4 downregulation kinetics in these cells
should provide insight into the physiologic processes
occurring during HIV-1 infection.
Previous studies have shown that T cells have large intrac-
ellular stores of CXCR4 that can be mobilized by treating
the cells with PMA and ionomycin [17]. Indeed, in order
to observe SDF-1 induced CXCR4 degradation in Jurkat
cells, we needed to inhibit the synthesis of new receptors
continuously with cycloheximide and incubate the cells
with SDF-1, PMA and ionomycin (Fig. 3A). Efficient
expression of HIV-1 Gag was achieved by transducing Jur-Page 3 of 14
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SDF-1 induced CXCR4 downregulation is TSG101-dependentFigure 1
SDF-1 induced CXCR4 downregulation is TSG101-dependent. (A) COS-1 cells co-transfected with HA-tagged 
CXCR4 and either GFP, TSG101-GFP, or siRNA directed against TSG101, as indicated, were incubated with an anti-HA anti-
body for 1 hour on ice. Cells were then either fixed and stained with a secondary antibody to detect cell surface CXCR4 (first 
row), or incubated in DMEM/10% FBS without SDF (second row) or with 100 nM SDF (third and fourth rows) for 3 hours at 
37°C prior to fixation, permeabilization and secondary-antibody staining. The cells were then analysed for GFP fluorescence 
(green), or CXCR4 expression (red). Blue represents nuclear staining. Scale bars = 10 µm. (B) Immunoblot of COS-1 cells co-
transfected with HA-tagged CXCR4 and siRNA directed against either TSG101 or LacZ. Top panel, TSG101 Western blot; 
bottom panel, actin Western blot.
Virology Journal 2008, 5:23 http://www.virologyj.com/content/5/1/23kat cells with Gag-GFP-encoding lentiviruses. At a multi-
plicity of infection (MOI) of 10, over 90% of the cells
expressed Gag-GFP (Fig. 3B). Incubation of Gag-GFP
expressing Jurkat cells with SDF-1, PMA and ionomycin
revealed that downregulation of endogenous CXCR4 was
clearly attenuated by expression of wt Gag-GFP (Fig.
3C,D,E). In contrast, cells expressing the late domain
mutant, LTAL Gag-GFP, exhibited CXCR4 degradation
rates more similar to the LacZ control (Fig 3D,E). Notably,
cell surface levels of CXCR4 at steady state were not
altered in HIV-1 Gag expressing cells (Fig. 3F). Thus,
experiments in Jurkat cells reveal that expression of HIV-1
Gag attenuates downregulation of endogenous CXCR4 in
the presence of SDF-1, PMA and ionomycin. These data
are similar to those reported in Figure 2, for SDF-I induced
HA-CXCR4 degradation.
PMA-induced lysosomal degradation of CD4 is 
independent of TSG101 and Vps4
CD4 is a cell surface transmembrane glycoprotein whose
endocytic trafficking is of great significance to the HIV-1
life cycle. Previous studies have shown that PMA induces
internalization and lysosomal degradation of CD4. How-
ever, the role of the ESCRT complexes in CD4 downregu-
lation is not known, nor is it known how, or if HIV-1 Gag
expression affects this process.
Previous studies have quantitated CD4 degradation kinet-
ics by monitoring levels of metabolically (pulse) labeled
CD4 over time in untreated and PMA-treated cells
[24,33,34]. Pulse labeled CD4 has been shown to proceed
to the cell surface via the secretory pathway within 30–60
minutes after synthesis, internalize via endocytosis, and
undergo degradation in lysosomes [34]. We were unable
to immunoprecipitate endogenous CD4 from Jurkat T
cells using a wide range of available anti-CD4 antibodies.
We therefore examined PMA-induced downregulation of
exogenously expressed CD4, which was readily radiola-
beled and immunoprecipitated using a monoclonal anti-
CD4 (Leu3a) antibody. Trafficking of exogenous CD4 has
been shown to accurately represent that of endogenous
CD4 [35], and we have previously shown that CD4 is traf-
ficked to the cell surface in transfected COS-1 cells
[36,37].
COS-1 cells expressing exogenous CD4 were metaboli-
cally labeled with 35S-Met/Cys-translabel for 10 minutes,
then chased in non-radioactive medium in the presence or
absence of PMA. PMA induced a significant decrease in
CD4 levels over a period of 6 hours (Fig. 4A). The experi-
ment was then repeated in cells depleted of endogenous
TSG101 using siRNA. At early time points, CD4 degrada-
tion was slightly attenuated in TSG101 depleted cells (Fig.
4B, 2 hour time point). However, by 6 hours, CD4 was
degraded as efficiently in TSG101-depleted cells as in con-
trol cells. Under similar conditions of TSG101 knock-
down, EGF induced EGFR degradation was dramatically
inhibited (Fig. 4D).
HIV-1 Gag attenuates CXCR4 degradation in COS-1 cellsFigure 2
HIV-1 Gag attenuates CXCR4 degradation in COS-1 
cells. (A) COS-1 cells co-expressing HA-tagged CXCR4 
(red) and either wild type (top panels) or LTAL, a PTAP 
mutant form (bottom panels) of Gag-GFP (green) were 
treated as described in Figure 1A. Only cells that were incu-
bated for 3 hours in the presence of SDF are shown. Scale 
bars = 10 µm. (B) The percent of COS-1 cells that had no 
visible HA-CXCR4 remaining after 3 hours of incubation 
with SDF was determined for each of the conditions 
described in Figs. 1 and 2A. Data shown represents the mean 
± SD of 2 or more independent experiments. 50 to 100 cells 
were analyzed per experiment. (C) COS-1 cells co-express-
ing HA-CXCR4 and GFP or Gag-GFP were lysed at various 
times after SDF treatment and analyzed by SDS-PAGE and 
Western blotting with anti-pERK1/2 and anti-ERK antibodies, 
as indicated. One representative immunoblot (out of three 
independent experiments) is shown.Page 5 of 14
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HIV-1 Gag attenuates SDF-induced CXCR4 downregulation in Jurkat T cellsFigure 3
HIV-1 Gag attenuates SDF-induced CXCR4 downregulation in Jurkat T cells. (A) Jurkat T cells were pre-treated 
with cycloheximide, then incubated in the presence (filled squares) or absence (open squares) of SDF, PMA and ionomycin for 
the indicated times. At each time point, cells were lysed and analysed by SDS-PAGE and Western blotting with an anti-CXCR4 
polyclonal antibody. Western blots were quantitated and amount of CXCR4 remaining at each time point was determined as a 
percent of amount of CXCR4 at 0 hour. Data from one representative experiment (out of three) is shown. (B) Jurkat T cells 
were transduced with Gag-GFP encoding lentiviruses at the indicated MOIs. 48 hours post transduction, cells were analyzed 
for GFP fluorescence by flow cytometry. The % of GFP positive cells is indicated for each MOI. (C) A representative gel depict-
ing CXCR4 levels in Jurkat T cells transduced with lentiviruses encoding wild-type Gag-GFP and treated as described in (A) is 
shown. Control represents untransduced cells. (D) Quantitation of the gel shown in (C). Additionally, degradation of CXCR4 
in Jurkat T cells transduced with lentiviruses encoding LTAL Gag-GFP is shown. Error bars represent standard deviation 
between duplicates at each time point. (E) Jurkat T cells were transduced with lentivirus encoding LacZ (control), Gag-GFP or 
LTAL Gag-GFP. Data shown represents the mean ± SD of % undegraded CXCR4 remaining after 6 hours of incubation with 
SDF, PMA and ionomycin. (F) Cell surface levels of CXCR4 in Jurkat T cells expressing LacZ, Gag-GFP or LTAL Gag-GFP were 
determined 48 hours post transduction by flow cytometric analysis of cells stained with a biotinylated anti-CXCR4 antibody 
and Streptavidin-PE. Data shown represents the mean ± SD of surface CXCR4 levels relative to the control, from two inde-
pendent experiments.
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PMA-induced CD4 downregulation is TSG101 and Vps4 independentFigure 4
PMA-induced CD4 downregulation is TSG101 and Vps4 independent. (A) COS-1 cells transfected with CD4 were 
labeled with trans-35S-label for 10 minutes, then chased in non-radioactive medium in the presence or absence of 50 ng/ml 
PMA for the indicated times. At each time point, cells were lysed and radioactive CD4 was analyzed by immunoprecipitation, 
SDS-PAGE and phosphorimaging. The amount of CD4 remaining at each time point was determined as a percent of the 
amount of CD4 at the first chase time point, ie 0.5 hours. Data from one representative experiment (out of three) is shown. 
Error bars represent standard deviation between duplicates for each condition at each time point. (B) COS-1 cells co-trans-
fected with CD4 and siRNA against TSG101 or LacZ were treated as described in (A). Data from one representative experi-
ment (out of four) is shown. Also shown is an immunoblot of TSG101 and actin levels in COS-1 cells co-transfected with CD4 
and siRNA directed against either TSG101 or LacZ. (C) COS-1 cells co-expressing CD4 and either GFP or Vps4E228Q-GFP 
were treated as described in (A). Data from one representative experiment (out of three) is shown. (D) COS-1 cells were 
transfected with siRNA directed against either TSG101 or LacZ, serum-starved, and treated with 50 ng/ml EGF for 10 min. 
The cells were then washed, reincubated with fresh media for 0 or 3 hours, lysed and analysed by SDS-PAGE and Western 
blotting with an anti-pEGFR antibody. The percent of undegraded pEGFR remaining at 3 hour was determined for the two con-
ditions. Error bars represent SD between duplicates for each condition. (E) COS-1 cells were transfected with GFP or 
Vps4E228Q-GFP, serum-starved, and allowed to internalize EGF for 10 min. The cells were then washed, reincubated with 
fresh media for 3 hours and analysed for GFP fluorescence, or endogenous phosphoEGFR by immunofluorescence. The per-
centage of GFP positive cells with pEGFR remaining at 3 hours was determined for the two conditions. Error bars represent 
SD between duplicates for each condition.
Virology Journal 2008, 5:23 http://www.virologyj.com/content/5/1/23In order to determine whether the AAA-type ATPase Vps4
plays a role in PMA-induced CD4 downregulation, a
dominant negative form of Vps4 (Vps4E228Q-GFP) was
co-expressed with CD4. At early time points, CD4 degra-
dation was slightly attenuated, but by 6 h, Vps4E228Q-
GFP expressing cells had degraded CD4 as efficiently as
cells expressing GFP (Fig. 4C). In contrast Vps4E228Q-
GFP strongly inhibited EGF-induced EGFR degradation
(Fig. 4E). Taken together, these findings suggest that PMA-
induced CD4 degradation may be partially dependent on
TSG101 and Vps4 function and only during early times
after exposure to PMA. With prolonged PMA treatment,
CD4 degradation can proceed in the absence of functional
TSG101 and Vps4.
Expression of HIV-1 Gag does not affect PMA-induced 
CD4 degradation
We next determined whether expression of HIV-1 Gag
impinges on the ESCRT-independent downregulation of
CD4. Gag expressing cells, like TSG101-depleted and
Vps4E228Q overexpressing cells, exhibited an initial
slowdown in the rate of CD4 degradation, which was
completely overcome upon prolonged exposure to PMA
(Fig. 5A). In contrast, lysosomal inhibitors (ammonium
chloride and chloroquine) clearly inhibited CD4 degrada-
tion (Fig. 5B).
A summary of all the measurements of PMA-induced CD4
degradation represented as the percent of undegraded
CD4 remaining after 6 hours of PMA treatment is shown
in Fig. 5B. PMA-induced CD4 degradation was not
affected by either depletion of endogenous TSG101 or by
overexpression of Vps4E228Q or HIV-1 Gag, suggesting
that under these conditions, lysosomal degradation of
CD4 can proceed in the absence of ESCRT-I and Vps4.
Taken together, our studies clearly demonstrate that
downregulation of CXCR4, but not CD4, is attenuated by
HIV-1 Gag-mediated recruitment of ESCRT complexes.
Thus the ability of HIV-1 Gag to impinge on the cellular
endocytic pathway is selective, attenuating only ESCRT-
dependent processes in this pathway.
Discussion
In this study, we show that HIV-1 Gag, as well as TSG101,
differentially affect the kinetics of downregulation of the
HIV-1 co-receptors CXCR4 and CD4. SDF-1-induced
CXCR4 downregulation was sharply reduced when
TSG101 function is inhibited, while PMA-induced CD4
downregulation was relatively unaffected. Depleting
TSG101 using siRNA directed specifically against TSG101
has been shown to result in a reduction in the cellular lev-
els of the other two components of the ESCRT-I complex,
Vps28 and hVps37 [11]. Consequently, TSG101-depleted
cells have fewer functional ESCRT-I complexes. Thus, our
observations imply that CXCR4, but not CD4, is depend-
ent on the ESCRT-I complex for its lysosomal degradation.
Divergent receptors, such as the Epidermal Growth Factor
Receptor (EGFR) and the Toll-like receptor, TLR4, have
been shown to be dependent on Hrs, ESCRT-I and Vps4
for their transport from early endosomes to late endo-
somes to lumenal vesicles in the MVB [3,38]. However,
this is not the only route into the MVB. For example, sort-
ing and lysosomal degradation of the Delta Opioid Recep-
tor (DOR), a GPCR, is Hrs and Vps4 dependent but does
not require TSG101 (ESCRT-I) [21]. Another recent study
showed that lysosomal sorting of the GPCR, PAR-1 (Pro-
tease-activated receptor-1) does not require Hrs or
TSG101 [39]. Moreover, MVB sorting of the melanosome
protein Pmel17 is completely independent of any of the
members of the 'Vps' family of proteins [40]. It is also
important to note that not all ESCRT components are
essential for HIV-1 budding and release. For example,
depletion of ESCRT-II components or of AIP1/Alix has
minimal effects on HIV-1 budding [6,41]. These studies
clearly indicate that protein sorting and MVB biogenesis
are complex processes involving multiple points of entry
and regulation.
Besides modulating the levels of receptors at the cell sur-
face, the cellular endocytic pathway plays a major role in
the attenuation of ligand-induced receptor-mediated sig-
naling [42]. For EGFR and other Receptor Tyrosine
Kinases, sequestration of the activated receptor into the
internal vesicles of the MVB is required to shut down sig-
naling. This process occurs 2–3 hours after ligand binding.
Activated EGFR remains in early and late endosomes dur-
ing this time and is capable of mediating continued intra-
cellular signaling [43]. We previously showed that
expression of HIV-1 Gag increases the amount of EGFR
that remains in endosomes after EGF addition [14]. As a
consequence, Gag expressing cells exhibit hyperactivated
and prolonged MAP kinase signaling. Increased MAP
kinase activation is advantageous to the virus as it has
been shown to enhance HIV-1 replication and infectivity
[44,45].
In contrast, GPCR-mediated signaling is attenuated
within minutes after ligand binding. CXCR4, like most
GPCRs, is desensitized rapidly through the action of
GPCR kinases (GRKs), which phosphorylate the receptor
on several C terminal Ser/Thr residues [19]. Phosphoryla-
tion of CXCR4 promotes binding of β-arrestins, which
sterically hinder the association of heterotrimeric G pro-
teins with the receptor and thereby block signal transduc-
tion [46]. The increase in intracellular CXCR4 induced by
expression of HIV-1 Gag did not result in a change in SDF-
1 mediated CXCR4 signaling, as judged by MAP kinase
activation (Fig 2C). This finding is consistent with knownPage 8 of 14
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Gag expressing cells is desensitized and does not signal.
β-arrestin binding to GPCRs also serves to recruit compo-
nents of the endocytic machinery including clathrin and
AP-2, thereby mediating the internalization of the recep-
tor [47]. Following internalization, CXCR4 colocalizes
with Hrs-positive endosomes [20]. While Hrs and Vps4
have been implicated in CXCR4 downregulation [20], no
role for TSG101 or ESCRTs had been established in this
process until now. Our data (Figs 1, 2) strongly suggest
that SDF-1 induced CXCR4 downregulation is TSG101
and ESCRT-I dependent. Given that HIV-1 Gag competes
with Hrs for TSG101 in vitro [48], and that overexpression
of TSG101-binding regions of Hrs inhibits HIV-1 release
[49], we hypothesized that expression of Gag would com-
pete for TSG101 binding and function in vivo. Our obser-
vations that TSG101/ESCRT-I dependent downregulation
of CXCR4 (Figs 2, 3) and EGFR [14] are attenuated in HIV-
1 Gag expressing cells indicate that Gag functionally
depletes the ESCRT complexes, thereby interrupting other
ESCRT-dependent pathways in the cell.
Two other HIV-1 proteins, Nef and Env, have been shown
to interact with or regulate CXCR4. Thus, an important
question is whether levels of CXCR4 are altered in the
context of an HIV-1 infected cell. Multiple studies have
addressed this issue, primarily by quantitating the
amount of cell surface CXCR4. A recent study reported
that HIV-1 Nef induces downregulation of CXCR4 from
the cell surface of infected cells [50]. The authors propose
that Nef-mediated CXCR4 downregulation may protect
against superinfection. Superinfection is detrimental to
viral replication because the accumulation of uninte-
grated viral DNA results in the induction of cytopathic
effects in the host cell [51]. However, multiple other stud-
ies have shown that HIV-1 Nef does not downregulate cell
surface levels of CXCR4 [52-54] and that maximal protec-
tion from superinfection involves an unidentified mecha-
nism that is independent of CXCR4 downregulation [54].
Similarly, we observed no change in cell surface levels of
CXCR4 in HIV-1 Gag-expressing cells (Fig. 3F). In con-
trast, others have, in some cases, seen an upregulation in
cell surface expression of CXCR4 in HIV-1 infected CD4+
T cells [55]. SDF-1 induced CXCR4 signaling could poten-
tially be beneficial to viral replication since it results in the
activation of transcription factors such as NFκB [16],
which are known to increase HIV-1 LTR promoter activity
[44]. It is also important to note that HIV-1 Env protein
(shed from virus particles or infected cells) can bind to
CXCR4 and thereby trigger apoptotic signals. However,
CD4 and CXCR4 expression are both required for apop-
totic signaling by Env in CD4 T cells [56]. Since CD4 is
efficiently removed from the surface of productively
infected cells (see below), only uninfected/bystander CD4
T cells express both CD4 and CXCR4 and are therefore
susceptible to Env-induced apoptosis [56].
Thus, CXCR4 downregulation might not be essential for
HIV-1 replication. We speculate that during the late stages
of the viral life cycle when mostly structural proteins such
as Gag are expressed, SDF-1 induced CXCR4 downregula-
tion is attenuated resulting in the accumulation of
densensitized CXCR4 within intracellular compartments.
These receptors could, in the long run, contribute to main-
taining or replenishing the cell surface levels of CXCR4 in
HIV-1 infected cells.
Unlike SDF-induced CXCR4 downregulation, Gag expres-
sion had little to no effect on PMA-induced CD4 down-
regulation (Fig. 5). PMA is a phorbol ester that binds to
and activates protein kinase C (PKC) [57]. PKC is nor-
HIV-1 Gag does not attenuate PMA-induced CD4 downregu-lationFigure 5
HIV-1 Gag does not attenuate PMA-induced CD4 
downregulation. (A) COS-1 cells co-expressing CD4 and 
either GFP or Gag-GFP were treated as described in Fig. 5A. 
Data from one representative experiment (out of three) is 
shown. (B) Data shown represents the mean ± SD of % 
undegraded CD4 remaining after 6 hours of incubation with 
PMA in COS-1 cells under various conditions as indicated (n 
≥ 2).Page 9 of 14
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receptor and its associated CD4 [58]. Activated PKC phos-
phorylates CD4 on its cytoplasmic tail and induces CD4
internalization and lysosomal degradation [25,59]. Sev-
eral studies have shown that PMA treatment mimics the
mechanism of antigen induced CD4 downregulation
[23,60]. Surprisingly, little is known about how internal-
ized CD4 gets sorted into the internal vesicles of the MVB
prior to lysosomal degradation. In the present study, we
show that PMA-induced CD4 downregulation can occur
efficiently in the absence of functional ESCRT-I and Vps4
(Fig. 4) and that expression of HIV-1 Gag has no effect on
this process (Fig. 5). These findings indicate that Gag
affects only ESCRT-dependent processes. We therefore
predict that lysosomal degradation of CD4 should not be
impeded by Gag in an HIV-1 infected cell. Indeed, loss of
cell surface CD4 is a hallmark of HIV-1 infection [51].
After virus entry, it is essential that HIV-1 efficiently down-
regulates CD4 for multiple reasons. CD4 downregulation
is important to prevent superinfection of the infected cell
[61]. In addition, cross-linking of CD4 in the absence of T
cell receptor activation results in the generation of non-
proliferative or apoptotic signals [62]. Viral transcription
is also inhibited under these conditions [63]. Many stud-
ies have also reported that cells overexpressing CD4
exhibit a drastic inhibition of virion release [64,65]. More-
over, the presence of CD4 at the cell surface appears to sig-
nificantly reduce the infectivity of released virions [66,67].
Exactly how CD4 exerts these effects is unclear, but these
observations establish the critical need for HIV-1 to down-
regulate CD4 in infected cells. Three different viral pro-
teins, Nef, Env and Vpu have evolved to ensure that cell
surface CD4 is downregulated soon after entry (by the
early protein Nef) and that transport of newly synthesized
CD4 to the cell surface at late stages of infection is blocked
(by late proteins Env and Vpu) [51,68]. Thus, by the time
Gag proteins are expressed in an infected cell, most of the
surface CD4 has already been downregulated by Nef.
Conclusion
Our observations indicate that expression of HIV-1 Gag
functionally depletes cellular ESCRT complexes. As a con-
sequence, Gag expression modulates ESCRT-dependent
but not ESCRT-independent receptor sorting pathways in
the host cell. These findings are likely to be highly relevant
to HIV-1 pathogenesis as they shed light on the mecha-
nisms used by HIV-1 proteins to dysregulate normal cell
physiology and to potentiate viral replication.
Methods
Antibodies and reagents
The following antibodies were purchased as indicated:
anti-HA monoclonal (12CA5) and polyclonal antibodies
and anti-CXCR4 polyclonal antibody, Sigma (St. Louis,
MO); anti-phosphoERK monoclonal antibody and anti-
actin, anti-GFP, anti-phosphoEGFR and anti-ERK polyclo-
nal antibodies, Santa Cruz Biotechnology (Santa Cruz,
CA); anti-TSG101 monoclonal antibody, GeneTex. Inc
(San Antonio, TX); anti-EEA1 monoclonal antibody, BD
Transduction Laboratories (San Diego, CA); anti-CD63
monoclonal antibody, Cymbus Biotechnology Ltd (UK);
Biotinylated anti-mouse CXCR4, BD Pharmingen (San
Jose, CA); anti-β-Gal, Promega, (Madison, WI). Mono-
clonal anti-CD4 (leu3A) was used to immunoprecipitate
CD4. A homemade rabbit anti-p24CA antiserum was used
to detect Gag. Trans 35S-label was purchased from MP Bio-
medicals (Irvine, CA). SDF-1α was obtained from Pepro-
tech Inc. (Rocky Hill, NJ). PMA, Cycloheximide and
Chloroquine were purchased from Sigma (St. Louis, MO).
Ionomycin was obtained from Calbiochem-EMD Bio-
sciences (La Jolla, CA). EGF was obtained from Oncogene
Research Products (San Diego, CA). Streptavidin-PE was a
kind gift from Dr. Lionel Ivashkiv (Hospital for Special
Surgery, and Weill Graduate School of Medical Sciences of
Cornell University, New York, NY).
DNA plasmids and siRNA
The Rev independent Gag expression vectors pGag-GFP
and LTAL Gag-GFP have been described elsewhere
[14,69]. pEGFP-TSG101 (full length) was a kind gift from
Dr. Stanley Cohen (Stanford University, Stanford, CA).
3xHA-CXCR4 was obtained from the UMR cDNA resource
center (University of Missouri-Rolla, Rolla, MO). pEGFP-
N2 CD4 (full length) was a kind gift from Dr. John Wills
(Pennsylvania State University College of Medicine, Her-
shey, PA). VPS4E228Q-GFP was a kind gift from Dr. Uta
von Schwedler (University of Utah School of Medicine,
Salt Lake City, UT). siRNAs directed against human
TSG101 (5'-CCUCCAGUCUUCUCUCGUCTT-3') and
LacZ were obtained from the High Throughput Screening
Core Facility at Memorial Sloan Kettering Cancer Center
(New York, NY).
Cell culture and transfections
COS-1 cells were maintained in DMEM/10% fetal bovine
serum (FBS). For transfections, COS-1 cells were seeded to
approximately 50% density and transfected the next day
with 2 to 6 µg plasmid DNA using Lipofectamine 2000
(Gibco BRL Life Technologies, Carlsbad, CA). For TSG101
knockdown experiments, COS-1 cells were seeded to
approximately 30% density and transfected the next day
with 25 to 50 nM TSG101 or LacZ siRNA and 0.5 to 1 µg
plasmid DNA using Lipofectamine 2000 according to the
manufacturer's recommendations. 24 hours later, the cells
were transfected again with 25 to 50 nM TSG101 or LacZ
siRNA. Cells were harvested and analyzed for effects of
TSG101 knockdown the next day. Jurkat T cells were
maintained in RPMI/10% fetal bovine serum (FBS) sup-
plemented with 2 mM Glutamax (Gibco). For expression
of exogenous proteins, 1 × 105 Jurkat cells were trans-Page 10 of 14
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GFP or LTAL Gag-GFP at a multiplicity of infection (MOI)
of 10.
Lentivirus production and titration
TheViraPower™ Lentiviral Directional TOPO® Expression
Kit was purchased from Invitrogen (Carlsbad, CA). Rev-
independent wild type HIV-1 Gag GFP and the late
domain mutant, LTAL Gag GFP were TOPO®-cloned into
pLenti6/V5-D-TOPO®-plasmid as per the manufacturer's
instructions. After sequence verification, the pLenti6/V5-
D-TOPO®-expression plasmid was cotransfected with the
ViraPower™ Packaging Mix into the 293FT cell line to pro-
duce lentivirus. 48 hours later, the viral supernatant was
harvested and titered as follows. Three different dilutions
(1/100, 1/1000 and 1/10000) of the viral supernatant
were used to transduce 1 × 105 Jurkat T cells, in the pres-
ence of 6 µg/ml Polybrene®. On the next day, the trans-
duced Jurkat cells were pelleted at 150 × g and
resuspended in fresh RPMI/10% FBS/Glutamax. 48 hours
following transduction, Jurkat cells were analyzed by flow
cytometry (BD Biosciences FACSCalibur flow cytometer);
over 100,000 cells were analyzed for GFP expression. The
viral titers were calculated as follows Transduction units/
ml = (average cell number at time of transduction × % of
GFP-positive cells)/100 × dilution factor [70]. The opti-
mal multiplicity of infection (MOI) to be used was deter-
mined by transducing Jurkat T cells at various MOIs (0, 1
and 10), changing the media the next day, then analyzing
the cells by flow cytometry for GFP expression after
another 24 hours.
Immunofluorescence microscopy
Transfected COS-1 cells grown on coverslips were serum
starved for 16 hours, and then processed 48 hours post-
transfection [69]. HA-CXCR4 downregulation experi-
ments were performed as previously described [20].
Briefly, cell surface receptors were labeled with an anti-HA
antibody for 1 hour on ice, washed twice with cold PBS,
then incubated in DMEM/10% FBS with or without 100
nM SDF-1α for 3 hours at 37°C. After fixation and perme-
abilization, cells were incubated with an Alexa Fluor® 594-
conjugated secondary antibody (Molecular Probes,
Eugene, OR). Cells were then washed four times for 5
minutes each with PBS, and mounted on microscope
slides. For nuclear staining, HOECHST dye was added to
cells during the first PBS wash after secondary antibody
incubation. EGFP fluorescence was visualized directly.
Laser scanning confocal microscopy was performed on a
Zeiss LSM510 confocal microscope equipped with an
Axiovert 100 M inverted microscope using a 63×, 1.2-
numerical-aperture (NA) water immersion lens for imag-
ing as previously described [69]. We first determined the
percentage of cells that were initially expressing CXCR4
(X4t = 0h). Then we determined the percentage of cells that
had CXCR4 signal remaining after 3 hours of incubation
with SDF-1 (X4t = 3h). The degradation efficiency was cal-
culated as: [1 - (X4t = 3h/X4t = 0h)] × 100.
For colocalization experiments, cells were incubated with
monoclonal anti-EEA1 or monoclonal anti-CD63 anti-
body following the 3 hour SDF treatment. Cells were then
stained with the Alexa Fluor® 594-conjugated goat anti-
rabbit antibody (for HA-CXCR4) and a Cy5-conjugated
anti-mouse antibody (for EEA1 or CD63). Colocalization
was measured on a pixel-by-pixel basis using MetaMorph
software (Universal Imaging Corp., Downingtown, PA).
EGF-induced EGFR downregulation experiments were
performed as previously described [14].
CXCR4 signaling
Transfected COS-1 cells grown on 60 mm dishes were
serum starved for 16 hours. Cells were then treated with
100 ng/ml SDF for 0, 2, 10, 30 or 60 minutes at 37°C. At
each time point, cells were lysed in RIPA buffer (150 mM
NaCl, 1% NP-40, 0.5% Deoxycholic acid, 0.1% SDS, 50
mM Tris pH 8.0) containing leupeptin (10 ug/ml), apro-
tinin (10 ug/ml), AEBSF (0.25 mg/ml), NaF (1 mM) and
Na3VO4 (0.5 mM). Lysates were clarified at 20,800 × g in
an Eppendorf centrifuge for 10 min at 4°C. Western blot-
ting was performed using the indicated antibodies. Pro-
teins were detected using horseradish-peroxidase
conjugated secondary antibodies and ECL Western blot-
ting detection reagents using the manufacturer's instruc-
tions.
CXCR4 downregulation in Jurkat T cells
1 × 105 Jurkat T cells were pelleted at 150 × g, and incu-
bated in 50 µl of RPMI/10% FBS/2 mM Glutamax con-
taining 50 µg/ml cycloheximide for 15 minutes at 37°C.
50 µl of the same medium, either with or without 100 nM
SDF, 50 ng/ml PMA and 800 ng/ml Ionomycin was then
added and the cells were incubated at 37°C for 0, 1.5, 3,
6 or 9 hours. At each time point, cells were harvested,
washed once in PBS, lysed in 2 × SDS sample buffer by
sonication and proteins were resolved by SDS-PAGE.
Endogenous CXCR4 was detected using an anti-CXCR4
rabbit polyclonal antibody while expression of the Gag
and β-Gal proteins was determined using anti-p24CA and
anti-β-Gal antibodies respectively. Equal loading of pro-
teins was confirmed by detecting actin using an anti-actin
goat polyclonal antibody. Western blots were analyzed by
chemiluminescence (Pierce) and exposed to Biomax MR
films (Kodak, New Haven, Conn). Films were scanned
using an HP scanner and quantified using ImageGauge
Version 4.1 (FujiFilm).
Detection of Cell Surface levels of CXCR4 in Jurkat T cells
48 hours post transduction, Jurkat T cells were pelleted at
150 × g, and incubated with a biotinylated anti-CXCR4Page 11 of 14
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per 106 cells) for 30 minutes, on ice. Cells were then
washed in staining buffer (PBS/1% FBS), incubated with
Streptavidin-PE (1:500) for 30 minutes on ice, washed
and resuspended in staining buffer. PE fluorescence was
analyzed by flow cytometry (BD Biosciences FACSCalibur
flow cytometer).
Metabolic labeling and CD4 downregulation
Transfected COS-1 cells were metabolically labeled as
described previously [71], using 50 µCi/ml Trans 35S-
label. The cells were pulse-labeled for 10 minutes at 37°C,
then chased in DMEM/10%FBS containing 100 µM
cysteine and methionine, with or without 50 ng/ml PMA,
for 0.5, 2, 4 and 6 hours. At each time point, cells were
washed once with STE then lysed in RIPA buffer (150 mM
NaCl, 1 mM EDTA, 0.1% SDS, 0.5% deoxycholate, 1%
Triton-X 100, 10 mM Tris, pH 7.4) containing protease
inhibitors (10 µg/ml aprotinin, 10 µg/ml leupeptin and
0.25 mg/ml AEBSF). The lysates were clarified at 100,000
× g in a Beckman TL-100 ultracentrifuge for 15 minutes at
4°C. About 20 µl of the clarified lysate was kept aside
(sample before IP) and the rest of the lysate was then incu-
bated overnight at 4°C with 2.5 µg mouse anti-CD4
(Leu3a) antibody and 15 µl protein A/G plus agarose
beads (Santa Cruz, CA). The beads were washed three
times in RIPA buffer containing protease inhibitors.
Immunoprecipitated CD4 was eluted from the beads by
adding 2 × SDS sample buffer. The beads were boiled and
pelleted, and the eluted sample was analyzed by SDS-
PAGE and phosphorimaging using the Fluoro image ana-
lyzer FLA-5000 (FujiFilm, Stamford, CT). Images were
quantified using ImageGauge version 4.1 (FujiFilm).
Samples before IP were also subjected to SDS-PAGE and
Western blotting to determine levels of actin and other
exogenous proteins in the samples. To test the effect of lys-
osomal inhibitors on PMA-induced CD4 downregulation,
the experiment described above was performed using
medium containing 50 mM NH4Cl and 100 µM chloro-
quine.
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